Loading…
Gland Pharma (GLAND)₹3,302+5.41%Pharmaceuticals
Gland Pharma is compared with the 10 closest in size in Pharmaceuticals (229 companies in the industry). It has a P/E of 48.4 against a peer median of 42.0, and ROCE of 15.0% against a peer median of 21.0%, and latest-quarter sales growth of 19.7% against a peer median of 19.7%. By market cap it is #5 of 11 in this set.
As of · Peer set: 10 closest in size in Pharmaceuticals
| Company | M-cap (₹ Cr) | P/E | ROCE % | ROE % | Debt / equity | Div. yield % | Sales (₹ Cr) | Net profit (₹ Cr) | Qtr sales growth % | Qtr profit growth % | Compare |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Glenmark Pharmaceuticals | 75,325 | 42.0 | 40.1 | 30.5 | 0.06 | 0.1 | 16,989 | 1,362 | 23.2 | 927.6 | vs GLAND |
| Alkem Laboratories | 64,547 | 29.9 | 21.0 | 18.8 | 0.15 | 1.0 | 14,712 | 2,360 | 11.0 | −22.0 | vs GLAND |
| Biocon | 60,066 | 108.4 | 4.0 | 1.4 | 0.45 | 0.1 | 16,993 | 369 | 10.0 | 54.0 | vs GLAND |
| Abbott India | 56,562 | 36.6 | 45.1 | 34.4 | 0.04 | 2.0 | 6,909 | 1,554 | 6.4 | 7.6 | vs GLAND |
| Gland Pharma | 54,490 | 48.4 | 15.0 | 10.7 | 0.03 | 0.6 | 6,440 | 1,026 | 19.7 | 47.5 | — |
| IPCA Laboratories | 49,726 | 38.0 | 17.1 | 15.7 | 0.10 | 0.3 | 9,591 | 1,186 | 20.7 | 82.0 | vs GLAND |
| GlaxoSmithKline Pharmaceuticals | 45,799 | 42.8 | 61.1 | 45.5 | 0.01 | 2.1 | 3,818 | 1,038 | 16.6 | 15.6 | vs GLAND |
| Emcure Pharmaceuticals | 42,108 | 41.5 | 24.0 | 20.0 | 0.31 | 0.2 | 9,187 | 940 | 22.8 | 35.8 | vs GLAND |
| Ajanta Pharma | 41,800 | 33.1 | 35.0 | 27.0 | 0.06 | 1.8 | 5,442 | 1,055 | 32.4 | 49.3 | vs GLAND |
| Sai Life Sciences | 38,940 | 107.0 | 20.0 | 15.4 | 0.12 | 0.0 | 2,197 | 349 | 11.6 | 21.6 | vs GLAND |
| Wockhardt | 32,910 | 81.0 | 8.0 | 6.1 | 0.45 | 0.0 | 3,364 | 199 | 26.0 | — | vs GLAND |
| Peer median | 49,726 | 42.0 | 21.0 | 18.8 | 0.10 | 0.3 | 6,909 | 1,038 | 19.7 | 41.6 |
Listed companies closest to Gland Pharma in Pharmaceuticals include Glenmark Pharmaceuticals, Alkem Laboratories, Biocon, Abbott India, IPCA Laboratories, GlaxoSmithKline Pharmaceuticals, Emcure Pharmaceuticals, Ajanta Pharma.
Glenmark Pharmaceuticals, with a market cap of ₹75,325 Cr.
Gland Pharma trades at a P/E of 48.4; the median of its peer set is 42.0. A P/E above or below the median is a description, not a judgement on value.
Gland Pharma's return on capital employed is 15.0%, below the peer median of 21.0%.